
## AML KNOW the Facts



**Every 35 seconds**, someone somewhere in the world receives the shattering news that they have been diagnosed with blood cancer.<sup>1</sup> Leukemia is one type of blood cancer that affects the blood and bone marrow. Its most aggressive form is called acute myeloid leukemia (AML), in which immature types of blood cells (myeloblasts) are stopped at an early stage of their normal development. AML has the lowest five-year survival rate of all leukemias.<sup>2</sup> It can progress quickly and would probably be fatal within a couple of months if left untreated.<sup>3</sup>



For more than 30 years, the standard of care for the treatment of AML went unchanged in part due to the complex biology of AML.<sup>1,2</sup> While a few new treatments have been approved recently, there is still significant unmet need and much work to be done to continue to expand the treatment options available for patients with AML. Our investigational AML Franchise is evaluating a portfolio of therapies that leverage three distinct strategies for the treatment of AML. We will evaluate combination regimens including these and other compounds for their potential to change the standard of care for patients with AML.

<sup>1</sup> Krug U, et al. Leukemia. 2016;30:1230-1236. <sup>2</sup> Dohner H, et al. Blood. 2010;115(3):453-474.

**#KnowAML**